Literature DB >> 12005084

Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants.

Qibo Zhang1, Emily Pettitt, Roger Burkinshaw, Gillian Race, Lynne Shaw, Adam Finn.   

Abstract

BACKGROUND: Serogroup C meningococcal conjugate polysaccharide vaccines have been reported to induce significant serum IgG antibodies and immunologic memory in infants. Because meningococcus is a mucosal pathogen colonizing the nasopharynx, local mucosal immune responses may play an important role in host defense against infection and carriage. We have investigated the mucosal IgA and IgG antibody responses to two meningococcal C conjugate vaccines in the saliva of healthy infants.
METHODS: Specific salivary IgA and IgG antibodies to two meningococcal C polysaccharide conjugate vaccines (Menjugate from Chiron Corp., n = 46; and Meningitec from Wyeth Lederle, n = 54) were investigated by immunoassay in infants after parenteral vaccinations at the ages of 2, 3 and 4 months. Unstimulated saliva samples were collected immediately before the first immunization and 1 month after the third immunizations. Forty healthy infants receiving the same routine vaccines but no meningococcal C vaccine were recruited as controls.
RESULTS: There were significant increases in meningococcal C polysaccharide-specific IgG antibody concentrations postvaccination compared with prevaccination concentrations in both vaccinated groups (both P < 0.001), but no change in the control group. There were no significant increases in specific IgA postvaccination geometric mean concentrations in either the vaccine or the control groups. The number of IgA positives postvaccination increased slightly in the Wyeth vaccine group vs. controls (P < 0.05).
CONCLUSIONS: Significant salivary IgG antibodies to meningococcal C polysaccharide were observed after parenteral immunization with two meningococcal C conjugate vaccines, whereas there was no significant increase in specific IgA antibody levels for these two vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12005084     DOI: 10.1097/00006454-200203000-00010

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  8 in total

Review 1.  Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.

Authors:  Q Zhang; A Finn
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

2.  Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.

Authors:  Ingeborg S Aaberge; Philipp Oster; Oddveig S Helland; Anne-Cathrine Kristoffersen; Ellen Ypma; E Arne Høiby; Berit Feiring; Hanne Nøkleby
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

3.  Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-01-26

4.  Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.

Authors:  H Findlow; R Borrow; P Hardelid; E Newton; S Frankland; S Naylor; E Miller; E Kaczmarski; R C Read
Journal:  Clin Vaccine Immunol       Date:  2011-01-19

5.  Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal.

Authors:  Fatema A Legrand; Douglas F Nixon; Christopher P Loo; Erika Ono; Joan M Chapman; Maristela Miyamoto; Ricardo S Diaz; Amélia M N Santos; Regina C M Succi; Jacob Abadi; Michael G Rosenberg; Maria Isabel de Moraes-Pinto; Esper G Kallas
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

Review 6.  The relationship between mucosal immunity, nasopharyngeal carriage, asymptomatic transmission and the resurgence of Bordetella pertussis.

Authors:  Christopher Gill; Pejman Rohani; Donald M Thea
Journal:  F1000Res       Date:  2017-08-25

7.  In vitro cell culture model of human nasal-associated lymphoid tissue (NALT) to evaluate the humoral immune response to SARS-CoV-2 spike proteins.

Authors:  Waleed H Mahallawi; Talal M Aljeraisi
Journal:  Saudi J Biol Sci       Date:  2021-04-24       Impact factor: 4.219

Review 8.  The Pertussis resurgence: putting together the pieces of the puzzle.

Authors:  Rotem Lapidot; Christopher J Gill
Journal:  Trop Dis Travel Med Vaccines       Date:  2016-12-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.